OR WAIT null SECS
Element’s acquisition of Nanosyn is the latest in a series of moves made to strengthen the company’s North American presence.
Element Materials Technology announced the acquisition of Nanosyn, a pharmaceuticals contract development and manufacturing organization, on Oct. 11, 2021. This acquisition gives Element access to Nanosyn’s three 100,000 ft² facilities as well as over 75 scientists and experts.
According to a company press release, the acquisition of Nanosyn will greatly increase Element’s offering for customers in North America. Nanosyn’s facilities are all located in the San Francisco Bay area, whereas Element’s headquarters are in London.
The acquisition of Nanosyn is the latest in a series of moves made by Element to strengthen their life sciences services in 2021. Nanosyn is the fifth life sciences company Element acquired this year. Most recently, they acquired another North America-based company, Impact Analytical, in September.
“Nanosyn complements Element’s life sciences offering by extending our services to include drug discovery and small-scale manufacturing for drug development, making us a source of support and true partner for the full value chain,” said Jo Wetz, Element’s CEO, in the press release. “Nanosyn has a deep customer base that includes several of the top pharmaceutical companies in the world, and it supports the development of Element’s position as a full-service solutions provider.”
“Nanosyn has a 23-year track record of supporting numerous drug discovery and development programs which have led to over 50 clinical candidates and several marketed drugs,” said Nikolai Sepetov, Nanosyn’s CEO, in the press release. “Joining Element as it expands its life sciences offering will create the opportunity for us to be at the forefront of progress and development in the pharmaceutical industry.”